Clont is a prodrug that is used to treat blood clots. The irreversible binding of its active metabolite to the P2Y12 class of ADP receptors on platelets suppresses platelet activation and aggregation. Platelet aggregation inhibition is dose-dependent and visible 2 hours after single oral dosages. On the first day, repeated 75 mg doses decrease ADP-induced platelet aggregation, and inhibition achieves a stable state between Days 3 and 7.
Acute Coronary Syndrome: In patients who need an antiplatelet effect within hours, initiate clopidogrel with a single 300 mg (4 tablets) oral loading dose and then continue at 75 mg once daily. Initiating it without a loading dose will delay the establishment of an antiplatelet effect by several days.
Recent MI, Recent Stroke, or Established Peripheral Arterial Disease: 75 mg once daily orally without a loading dose.
It is given orally with or without food.
NSAIDs, warfarin, and selective serotonin and serotonin-norepinephrine reuptake inhibitors (SSRIs, SNRIs): NSAIDs, warfarin, and selective serotonin and serotonin-norepinephrine reuptake inhibitors (SSRIs, SNRIs): CYP2C19 inhibitors (omeprazole or esomeprazole): Increases the risk of bleeding. Avoid taking omeprazole or esomeprazole at the same time.
Repaglinide (substrates for CYP2C8): Clopidogrel should not be taken with Repaglinide since it raises Repaglinide plasma level.
Clont should not be used if you have any of the following conditions: Hypersensitivity to the medicine or any of the product's components. Peptic ulcer or cerebral hemorrhage are examples of active pathological bleeding.
Clont is generally a well-tolerated drug.
· Common side effects: bleeding, diarrhea, gastrointestinal upset, bleeding, skin reactions.
· Rare side effects: acquired hemophilia, anemia, angioedema, joint pain, arthritis, bone marrow disease.
In pregnant women, there are no sufficient and well-controlled trials. It should only be used during pregnancy if absolutely necessary. Clont is not known to be excreted in human breast milk. Considering the medicine's value to the mother, a decision should be taken whether to quit nursing or discontinue the drug.
Since it is a prodrug, the metabolism of its active metabolites is affected by CYP2C19 (weak metabolizer) gene mutations and drugs that inhibit CYP2C19 (such as omeprazole and esomeprazole). Simultaneous use of these drugs and CYP2C19 weak metabolizers may reduce the antiplatelet activity of clopidogrel.
· Because it inhibits platelet aggregation during the entire life cycle (710 days) of platelets, it may increase the risk of bleeding. In order to restore hemostasis, platelet transfusion within 4 hours after the loading dose or within 2 hours after the maintenance dose may be less effective.
· Discontinuation of clopidogrel increases the risk of cardiovascular events. If you stop 5 days before the elective surgery, you have a higher risk of bleeding. Clopidogrel treatment was resumed immediately after hemostasis.
· Thrombotic thrombocytopenic purpura (TTP) that requires emergency treatment has been reported, including plasma exchange (plasma exchange).
· In patients receiving clopidogrel or patients with a history of allergies to other thienopyridines, allergies have been reported, including skin rash, angioedema, or hematological reactions.
Keep the temperature below 30°C and away from light and moisture. Keep out of children's reach.